DCDeborah J. Clegg

Deborah J. Clegg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Deborah J. Clegg has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Determinants of body fat distribution in humans may provide insight about obesity-related health risks

    by Aaron P. Frank, Roberta de Souza Santos, Biff F. Palmer, Deborah J. Clegg


  • Sex, Gender, and Transgender: Metabolic Impact of Cross Hormone Therapy

    by Roberta de Souza Santos, Aaron P. Frank, Michael Douglas Nelson, Maurice M. Garcia, Biff F. Palmer, Deborah J. Clegg

    Most preclinical and clinical, animal, and human research has been biased with respect to sex and even more so with respect to gender. In fact, little is known about the impact of sex and even less about the influence of gender on overall metabolic processes. The National Institutes of Health has recognized this gap in scientific knowledge and now mandates that studies be conducted in both sexes and to include gender as variables influencing physiological processes such as metabolism. It is therefore critical to understand and appreciate how to incorporate sex and gender in preclinical and clinical research in order to enhance our understanding of the mechanisms by which metabolic processes differ by sex and gender. In this chapter, we define sex and gender and discuss when sex and gender are not aligned, such as that which occurs in transgender individuals, and how this impacts metabolic processes. We discuss the importance of understanding the influence and interactions between sex hormones and sex chromosomes rather than focusing on their relative contributions to metabolism in isolation. This knowledge will optimize therapies specific for individuals which need to encompass sex and gender.


  • The impact of sex and sex hormones on cell function

    by Roberta de Souza Santos, Aaron P. Frank, Deborah J. Clegg


  • Open Access

    The effects of 17 alpha-estradiol to inhibit inflammation in vitro

    by Roberta S. Santos, Luciana A. de Fatima, Aaron P. Frank, Everardo M. Carneiro, Deborah J. Clegg

    17 Alpha-estradiol (17 α-E2) is a natural, non-feminizing stereoisomer of 17 beta-estradiol (17 β-E2). Whereas much is known about the physiological effects of 17 β-E2, much less is known about 17 α-E2. For example, 17 β-E2 exerts anti-inflammatory effects in neurons and adipocytes through binding and activation of estrogen receptor alpha (ERα); however, if 17 α-E2 has similar effects on inflammation is currently unknown. To begin to address this, we analyzed the ability of 17 α-E2 and 17 β-E2 to suppress lipopolysaccharide (LPS)-induced inflammation in vitro using embryonic fibroblast cells (MEF) from wild type and total body ERα (ERKO) male and female mice. Additionally, we further probed if there were sex differences with respect to the effects of E2s using primary pre-adipocyte cells from C57BL/6J male and female mice. Also, we probed mechanistically the effects of E2s in fully differentiated 3T3-L1 cells. Both E2s decreased LPS-induced markers of inflammation Tnf-α and Il-6, and increased the anti-inflammatory markers Il-4 and IL-6 receptor (Il-6ra) in MEF cells. To begin to understand the mechanisms by which both E2’s mediate their anti-inflammatory effects, we probed the role of ERα using two methods. First, we used MEF cells from ERKO mice and found reductions in ERα diminished the ability of 17 α-E2 to suppress Tnf-α in female but not in male cells, demonstrating a sexual dimorphism in regard to the role of ERα to mediate 17 α-E2’s effects. Second, we selectively reduced the expression of ERα in 3T3-L1 cells using siRNA and found reductions in ERα diminished the ability of both E2s to suppress Tnf-α and Il-6 expression. Lastly, to determine the mechanisms by which E2s reduce inflammation, we explored the role of NFκB-p65 and found both E2s decreased NFκB-p65 expression. In conclusion, we demonstrate for the first time that 17 α-E2, as well as 17 β-E2, suppresses inflammation through their effects on ERα and NFκB-p65.


  • Open Access

    Challenges in Treating Cardiovascular Disease: Restricting Sodium and Managing Hyperkalemia

    by Deborah J. Clegg, Michael Cody, Biff F. Palmer


  • Non‐shivering thermogenesis as a mechanism to facilitate sustainable weight loss

    by B. F. Palmer, D. J. Clegg

    Summary: Currently, there is a significant percentage of the population who are or will be classified as obese, necessitating novel strategies to facilitate sustainable weight loss. Reductions in basal metabolic rate occur in the face of weight loss and pose formidable barriers to individuals attempting to sustain meaningful weight reductions. Here, we discuss the mechanisms by which non‐shivering thermogenesis may provide insight into metabolic pathways that can become druggable targets to facilitate sustainable weight loss. Specifically, we highlight the fact that non‐shivering thermogenesis results in activation and expansion of brown and beige adipose tissues as well as activates pathways in skeletal muscle which increase metabolic flux and activity of muscle fibres through futile calcium cycling across the endoplasmic reticulum all facilitating an increase in metabolism. Finally, we highlight the fact there are sexual dimorphisms with respect to these metabolic processes in keeping with the National Institutes of Health mandate of treating sex as a biologic variable.


  • Open Access

    Sex and gender matter to biology

    by Aaron Frank, Deborah Clegg

    Flip through a few TV channels or browse the Internet for a bit and you will be quickly reminded that, in our day and age, everyone is thinking about ‘sex’. Biologists think about sex too – albeit more in the biological sense than the act itself. The problem is they don't think enough about it. Indeed, though most animals display marked differences in sexual anatomy and reproductive function, sex is regularly overlooked in biomedical research at both the clinical and basic science levels1. Over 25 years ago, The National Institutes of Health recognized this as problematic; exclusion of women from large clinical trials blunted their ability to detect sex differences in the safety and efficacy of therapeutic drugs. In 2001, the Institute of Medicine echoed these concerns, calling for expansion of research into sex differences at the biochemical and cellular levels2. Despite this, investigators still regularly ignore the sex of cell lines studied in vitro2, as well as failing to include both sexes in animal studies. In this article, we briefly discuss the nature of sex differences and highlight their importance to future basic and translational research.

  • Open Access

    Estrogens modulate ventrolateral ventromedial hypothalamic glucose-inhibited neurons

    by Ammy M. Santiago, Deborah J. Clegg, Vanessa H. Routh


  • Open Access

    Transwomen and the Metabolic Syndrome: Is Orchiectomy Protective?

    by Michael D. Nelson, Lidia S. Szczepaniak, Janet Wei, Edward Szczepaniak, Francisco J. Sánchez, Eric Vilain, Jennifer H. Stern, Richard N. Bergman, C. Noel Bairey Merz, Deborah J. Clegg

    Background: Male-to-female transsexual women or transwomen who undergo cross-sex hormone treatments experience increased health-related risks (e.g., increased rates of cardiovascular disease and premature death). Yet, the exact mechanism by which altering biochemistry leads to metabolic impairment remains unclear. While much attention has been paid to cross-sex hormone therapy, little is known about the metabolic risk associated with orchiectomy. Methods: To address the above limitation, we prospectively enrolled 12 transwomen: 4 who had undergone bi-lateral orchiectomy and 8 who had not. Both groups were using cross-sex hormones. Glucose tolerance was assessed using a standard 75g oral glucose tolerance test. Hepatic steatosis was assessed by 1 H magnetic resonance spectroscopy. The amount of subcutaneous and visceral abdominal fat was determined from a single abdominal axial image at the level between the vertebral L2 and L3 bodies. Baseline venous fasting blood sampling was performed for measurement of hemoglobin A1c, glucose, insulin, sex hormones, and sex hormone binding globulin. Results: The major novel findings were: (1) orchiectomy and cross-sex hormone therapy is associated with less hepatic steatosis and insulin resistance; (2) orchiectomy may be metabolically protective, and (3) circulating concentrations of sex hormones may be a major determinant of metabolic health in transwomen. Conclusions: To our knowledge, this is the first study to suggest an independent and protective role of orchiectomy on the metabolic health of transwomen.